Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 May;82(5):186-230.
doi: 10.1016/j.jinf.2021.02.002. Epub 2021 Feb 5.

Early clinical experience with imatinib in COVID-19: Searching for a dual effect

Alejandro Morales-Ortega  1 , Luis Rivas-Prado  2 , Begoña Frutos-Pérez  2 , Beatriz Jaenes-Barrios  3 , Ana Isabel Farfán-Sedano  2 , Carlos Javier García-Parra  4 , Belén Hernández-Muniesa  5 , Miguel Ángel Duarte-Millán  2 , Elena Madroñal-Cerezo  2 , Ana Ontañón-Nasarre  5 , José Manuel Ruiz-Giardín  2 , Fernando Bermejo  6 , Mario García-Gil  5 , Sonia Gonzalo-Pascua  2 , Juan Víctor San Martín-López  2 , David Bernal-Bello  2
Affiliations
Comment

Early clinical experience with imatinib in COVID-19: Searching for a dual effect

Alejandro Morales-Ortega et al. J Infect. 2021 May.

Abstract

Image, graphical abstract

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interests David Bernal-Bello is the principal investigator of a non-sponsored randomised trial investigating the therapeutic role of imatinib and baricitinib in COVID-19 patients (NCT04346147). The rest of the authors are sub-investigators in this project. All authors declare no other competing interests.

Figures

Image, graphical abstract
Graphical abstract
See this image and copyright information in PMC

Comment on

References

    1. Chen P.J., Chao C.M., Lai C.C. Clinical efficacy and safety of favipiravir in the treatment of COVID-19 patients. J Infect. 2020 10.1016/j.jinf.2020.12.005 [Epub ahead of print] - PMC - PubMed
    1. Chan H.T., Chao C.M., Lai C.C. Sofosbuvir/daclatasvir in the treatment of COVID-19: a meta-analysis. J Infect. 2020 10.1016/j.jinf.2020.12.021 [Epub ahead of print] - PubMed
    1. Ingraham N.E., Lotfi-Emran S., Thielen B.K., et al. Immunomodulation in COVID-19. Lancet Respir Med. 2020;8:544–546. - PMC - PubMed
    1. Morales-Ortega A., Bernal-Bello D., Llarena-Barroso C., et al. Imatinib for COVID-19: a case report. Clin Immunol. 2020;218 - PMC - PubMed
    1. Breccia M., Abruzzese E., Bocchia M., et al. Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey. Leukemia. 2020;34:2260–2261. - PMC - PubMed